Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Sarepta Therapeutics, Inc. or argenx SE because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Sarepta Therapeutics, Inc. and argenx SE compare based on key financial metrics to determine which better meets your investment needs.

About Sarepta Therapeutics, Inc. and argenx SE

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Latest Biotechnology and Sarepta Therapeutics, Inc., argenx SE Stock News

As of July 31, 2026, Sarepta Therapeutics, Inc. had a $1.6 billion market capitalization, compared to the Biotechnology median of $252.6 million. Sarepta Therapeutics, Inc.’s stock is down 30.9% in 2026, down 5.2% in the previous five trading days and down 11.28% in the past year.

Currently, Sarepta Therapeutics, Inc.’s price-earnings ratio is 23.3. Sarepta Therapeutics, Inc.’s trailing 12-month revenue is $2.2 billion with a 3.0% net profit margin. Year-over-year quarterly sales growth most recently was -1.9%. Analysts expect adjusted earnings to reach $4.786 per share for the current fiscal year. Sarepta Therapeutics, Inc. does not currently pay a dividend.

As of July 31, 2026, argenx SE had a $53.6 billion market cap, putting it in the 94th percentile of all stocks. argenx SE’s stock is up 1.5% in 2026, down 7% in the previous five trading days and up 42.57% in the past year.

Currently, argenx SE’s price-earnings ratio is 32.6. argenx SE’s trailing 12-month revenue is $5.3 billion with a 32.3% net profit margin. Year-over-year quarterly sales growth most recently was 214.9%. Analysts expect adjusted earnings to reach $28.590 per share for the current fiscal year. argenx SE does not currently pay a dividend.

How We Compare Sarepta Therapeutics, Inc. and argenx SE Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Sarepta Therapeutics, Inc. and argenx SE’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Sarepta Therapeutics, Inc. and argenx SE Stock Value Grades

Company	Ticker	Value
Sarepta Therapeutics, Inc.	SRPT	B
argenx SE	ARGX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Sarepta Therapeutics, Inc. has a Value Score of 61, which is Value. argenx SE has a Value Score of 9, which is Ultra Expensive.

The Value Stock Winner: Sarepta Therapeutics, Inc.

As you can clearly see from the Value Grade breakdown above, Sarepta Therapeutics, Inc. is considered to have better value than argenx SE. For investors who focus solely on a company’s valuation, Sarepta Therapeutics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Sarepta Therapeutics, Inc. and argenx SE’s Quality Grades

Company	Ticker	Quality
Sarepta Therapeutics, Inc.	SRPT	C
argenx SE	ARGX	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Sarepta Therapeutics, Inc. has a Quality Score of 53, which is Average. argenx SE has a Quality Score of 78, which is Strong.

The Quality Grade Winner: argenx SE

As you can clearly see from the Quality Grade breakdown above, argenx SE has a better overall quality grade than Sarepta Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, argenx SE could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Sarepta Therapeutics, Inc. and argenx SE’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Sarepta Therapeutics, Inc.	SRPT	C
argenx SE	ARGX	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Sarepta Therapeutics, Inc. has a Earnings Estimate Score of 45, which is Neutral. argenx SE has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: argenx SE

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, argenx SE has a better Earnings Estimate Revisions Grade than Sarepta Therapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, argenx SE could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Sarepta Therapeutics, Inc. and argenx SE Grades

In addition to Quality, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Sarepta Therapeutics, Inc. and argenx SE pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Sarepta Therapeutics, Inc. or argenx SE Stock?

Overall, Sarepta Therapeutics, Inc. stock has a Value Score of 61, Estimate Revisions Score of 45 and Quality Score of 53.

argenx SE stock has a Value Score of 9, Estimate Revisions Score of 63 and Quality Score of 78.

Comparing Sarepta Therapeutics, Inc. and argenx SE’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.